Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16247441rdf:typepubmed:Citationlld:pubmed
pubmed-article:16247441lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:16247441lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:16247441lifeskim:mentionsumls-concept:C0063566lld:lifeskim
pubmed-article:16247441pubmed:issue9lld:pubmed
pubmed-article:16247441pubmed:dateCreated2006-3-2lld:pubmed
pubmed-article:16247441pubmed:abstractTextThe erythroleukemia developed by spi-1/PU.1 transgenic mice is a multistep process. At disease onset, preleukemic cells are arrested in differentiation at the proerythroblast stage (HS1 stage) and their survival and growth are under the tight control of erythropoietin (Epo). During disease progression, malignant proerythroblasts characterized by Epo autonomous growth and in vivo tumorigenicity can be isolated (HS2 stage). During analysis of transcriptional profiling representive of discrete stages of leukemic progression, we found that the phosphatidylinositol 4-phosphatase type II gene was turned off in malignant cells. PI-4-phosphatase II is an enzyme that hydrolyses the 4-phosphate position of phosphatidylinositol-3-4-bisphosphate (PtdIns(3,4)P(2)) to form PtdIns(3)P. Using malignant cells engineered to stably express PI-4-phosphatase II, we showed that PI-4-phosphatase II reduced Akt activation level. Moreover, stimulation of malignant cells with Epo-induced PI-4-phosphatase II transcription pointing this gene as an Epo-responsive gene. This study provides first insight for a physiological role of PI-4-phosphatase II in the proerythroblast by controlling Epo responsiveness through a negative regulation of the PI3K/Akt pathway.lld:pubmed
pubmed-article:16247441pubmed:languageenglld:pubmed
pubmed-article:16247441pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16247441pubmed:citationSubsetIMlld:pubmed
pubmed-article:16247441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16247441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16247441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16247441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16247441pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16247441pubmed:statusMEDLINElld:pubmed
pubmed-article:16247441pubmed:monthMarlld:pubmed
pubmed-article:16247441pubmed:issn0950-9232lld:pubmed
pubmed-article:16247441pubmed:authorpubmed-author:Moreau-Gachel...lld:pubmed
pubmed-article:16247441pubmed:authorpubmed-author:DenisNNlld:pubmed
pubmed-article:16247441pubmed:authorpubmed-author:BarnacheSSlld:pubmed
pubmed-article:16247441pubmed:authorpubmed-author:Le ScolanEElld:pubmed
pubmed-article:16247441pubmed:authorpubmed-author:KosmiderOOlld:pubmed
pubmed-article:16247441pubmed:issnTypePrintlld:pubmed
pubmed-article:16247441pubmed:day2lld:pubmed
pubmed-article:16247441pubmed:volume25lld:pubmed
pubmed-article:16247441pubmed:ownerNLMlld:pubmed
pubmed-article:16247441pubmed:authorsCompleteYlld:pubmed
pubmed-article:16247441pubmed:pagination1420-3lld:pubmed
pubmed-article:16247441pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:meshHeadingpubmed-meshheading:16247441...lld:pubmed
pubmed-article:16247441pubmed:year2006lld:pubmed
pubmed-article:16247441pubmed:articleTitlePhosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene.lld:pubmed
pubmed-article:16247441pubmed:affiliationInserm U528, Institut Curie, Paris, France.lld:pubmed
pubmed-article:16247441pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16247441pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:234515entrezgene:pubmedpubmed-article:16247441lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:16247441lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16247441lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16247441lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16247441lld:pubmed